Developer docs
API playgroundTry for free, no card

Search company profiles

Acorn Biolabs

Full company profile

uuid0000uy4

Namestring
Acorn Biolabs
Legal namestring
Acorn Biolabs, Inc.
Websiteurl
acorn.me
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Acorn Biolabs is a Toronto-based, venture-backed biotech founded in 2017 that has built a hair follicle-derived stem cell banking and secretome production platform. The company's core technical premise is the non-invasive collection of 50 hair follicles in a 15-20 minute procedure, followed by laboratory processing and cryopreservation at -196°C to create a "regenerative reserve" of the customer's own stem cells. From these banked cells, Acorn produces personalized YOU™ secretome serums — full-spectrum preparations containing growth factors, exosomes, cytokines, and peptides — applied during clinical procedures (microneedling for skin rejuvenation; targeted delivery for hair growth support). Initial clinical data reports VEGF concentrations at 20x and EGF at 10x compared to a patient's own PRP.

The company serves three primary customer segments: aesthetic/cosmetic patients seeking skin rejuvenation, hair restoration seekers, and longevity/health-optimization enthusiasts pursuing biological insurance for future regenerative therapies. Revenue is generated through one-time collection and processing fees (~$945+tax), recurring annual or multi-year cryogenic storage fees ($190/year for individuals; multi-year prepaid packages at $1,650 for 5 years and $2,450 for 10 years), and per-treatment YOU™ secretome administration fees (~$945). Distribution operates through a hybrid model: a network of licensed provider clinics that perform collection and administer treatments, a direct e-commerce customer portal, and an Acorn Concierge clinic-matching service. Marketing leans heavily on content/earned media (Forbes, TechCrunch, Goop, Allure, Fast Company) and a referral program offering $190 account credits.

The company is in early commercial scale-up. It has raised approximately $14.3M CAD in cumulative funding (a $3.3M seed in 2019 and an $11M CAD Series A in June 2024 led by Merz Aesthetics), holds under 50 employees, operates dual Canadian and US legal entities, and is expanding into the US market with a clinical trial (NCT07227883) underway for facial skin rejuvenation. The CEO is founder Dr. Drew Taylor, and the Director of Product Development and Innovation is Amatullah Fatehi.

Short descriptiontext

Acorn Biolabs is a Toronto-based biotech (founded 2017) that non-invasively collects and cryopreserves customers' hair follicle stem cells, then produces personalized YOU™ secretome serums for skin rejuvenation and hair growth, selling direct to consumers and through a licensed provider clinic network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell banking, regenerative medicine, cryopreservation services, autologous cell therapy, personalized secretome treatments
Industry3 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Cell Banking Services
TypeSubscription Recurring
Description

One-time collection and processing fees plus recurring annual or multi-year storage fees for cryopreservation of hair follicle stem cells. Collection appointments at partner clinics cost approximately $945+ tax, with storage plans ranging from $190/year to $1,650 for 10 years for individuals.

acorn.me
2YOU™ Secretome Products
TypeOne Time License
Description

Personalized regenerative treatments (skin and hair) derived from the patient's own banked stem cells. These are applied through licensed provider clinics during procedures like microneedling. Initial clinical data shows significantly higher growth factor concentrations (VEGF at 20x, EGF at 10x) compared to PRP.

acorn.me
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details4 tiers
1Collection + 5 Years Storage
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$1,650+tax per person - Pre-paid all-inclusive package combining initial collection and 5 years of cryogenic storage

acorn.me
2Collection + 10 Years Storage
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$2,450+tax per person - Pre-paid all-inclusive package combining initial collection and 10 years of cryogenic storage

acorn.me
3Individual Annual Storage
ModelSubscriptionBilling cadenceAnnual
Notes

$190+tax yearly, $850+tax for 5 years, $1,650 for 10 years

acorn.me
4Family Annual Storage
ModelSubscriptionBilling cadenceAnnual
Notes

$350+tax yearly, $1,550+tax for 5 years, $3,050 for 10 years. Family plans consist of 2 adults + up to 4 additional family members residing at the same address.

acorn.me
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Acorn Biolabs collects, processes, and cryopreserves customers' own hair follicle-derived stem cells at -196°C for lifetime storage, then uses those banked cells to manufacture personalized secretome serums applied during clinical aesthetic procedures (e.g., microneedling) for skin rejuvenation and hair growth. The offering combines an upfront cell collection service with recurring cryogenic storage and downstream personalized regenerative treatments delivered through a network of licensed provider clinics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Growth factor concentrations in secretome show VEGF at 20x and EGF at 10x compared to patient's own PRP
+3 more records
Product overview1 text field

Acorn Biolabs offers a personalized regenerative medicine platform centered on hair follicle-derived stem cell banking and secretome-based treatments. The core offering consists of Cell Banking (cryopreservation of the customer's own stem cells harvested from hair follicles), paired with two personalized secretome serum products: YOU™ for Skin (for facial rejuvenation via microneedling) and YOU™ for Hair (for hair growth support). The secretome products are produced by culturing and processing the customer's banked cells to generate a concentrated regenerative serum containing growth factors, exosomes, and other bioactive molecules. A Future Pipeline extends into anti-aging, joint repair, and broader regenerative medicine applications. All treatments use the customer's own (autologous) cells, eliminating immune rejection risks.

Product and service4 records
1Cell Banking
CategoryCell Banking Services
Description

Cryopreservation service that collects and stores customers' hair follicle stem cells at -196°C for lifetime preservation, including initial collection of 50 hair follicles, laboratory processing, viability analysis, and long-term cryogenic storage for future regenerative treatments.

2YOU™ for Skin
CategoryPersonalized Regenerative Treatments
Description

A personalized secretome serum made from the customer's own banked stem cells, applied during microneedling procedures for facial skin rejuvenation. Contains concentrated growth factors and regenerative signals derived from the patient's hair follicle stem cells.

3YOU™ for Hair
CategoryPersonalized Regenerative Treatments
Description

A personalized secretome serum derived from the customer's own banked stem cells, designed to support natural, long-term hair growth at a cellular level by delivering concentrated regenerative signals to hair follicles.

4Acorn Concierge Provider Matching
CategoryService Delivery Channel
Description

Personal concierge service that matches customers with licensed clinic providers in the Acorn network based on their treatment goals and geographic location.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Dr. Steven Yoelin
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Dr. Steven Yoelin is serving as the principal investigator leading the randomized, blinded, controlled clinical trial (NCT07227883) evaluating YOU™ secretome product for facial skin rejuvenation. The trial is being conducted at a single investigational site in Newport Beach, California.

einpresswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

ExoCoBio is a South Korea-based exosome aesthetics company producing EXOVEL and other stem cell-derived exosome skincare products used in aesthetic clinics. It competes directly with YOU™ for Skin in the same provider channel.

TypeBroad incumbent
Description

EmCyte is an established regenerative medicine device company producing PRP and concentrated bone marrow aspirate systems used in aesthetic and orthopedic procedures. It is the incumbent against which YOU™ secretome competes on growth factor concentration.

TypeEmerging player
Description

Stemson is a San Diego-based regenerative medicine company developing iPSC-derived hair follicle therapies for hair loss. It addresses the same hair restoration use case as Acorn's YOU™ for Hair, but via a different (iPSC, allogeneic) technical approach.

TypeEmerging player
Description

Kimera Labs is a regenerative medicine company producing exosome-based products for both aesthetic and therapeutic indications, including skincare and hair restoration. It targets the same physician channel as Acorn with cell-derived regenerative products.

TypeEmerging player
Description

BENEV is a US medical aesthetics company that pioneered exosome-based regenerative skincare (Exosome Regenerative Complex) for in-office aesthetic procedures, making it a direct competitor to Acorn's YOU™ secretome microneedling offering.

TypeDirect peer
Description

Forever Labs is the most direct peer to Acorn, offering cryopreservation of young adult stem cells (from whole blood or adipose) for future regenerative use, targeting similar longevity and health-optimization consumers with a comparable subscription-based storage model.

TypeDirect peer
Description

Cryo-Cell is a publicly traded cell banking company specializing in cryopreservation of cord blood and menstrual blood-derived stem cells. It shares Acorn's core cryopreservation business model, though it focuses on different cell sources and a more traditional family/newborn banking customer base.

TypeDirect peer
Description

ViaCord (owned by Revvity/PerkinElmer) is a major cord blood and cord tissue banking service operating the same subscription-based cryopreservation business model as Acorn, although it focuses on newborn cells rather than adult hair follicle stem cells.

TypeDirect peer
Description

CBR, now part of CooperSurgical, is the largest US cord blood bank with a similar recurring-storage subscription model and direct-to-consumer acquisition approach, addressing expectant parents seeking biological insurance for their children.

TypeDirect peer
Description

StemCyte is a global cord blood and cellular therapy company operating a cryopreservation business closely comparable to Acorn's, including public cord blood banking and regenerative medicine research applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acorn Biolabs

Regenerative Medicineacorn.me

Acorn Biolabs is a Toronto-based biotech (founded 2017) that non-invasively collects and cryopreserves customers' hair follicle stem cells, then produces personalized YOU™ secretome serums for skin rejuvenation and hair growth, selling direct to consumers and through a licensed provider clinic network.

What Acorn Biolabs does

Acorn Biolabs is a Toronto-based, venture-backed biotech founded in 2017 that has built a hair follicle-derived stem cell banking and secretome production platform. The company's core technical premise is the non-invasive collection of 50 hair follicles in a 15-20 minute procedure, followed by laboratory processing and cryopreservation at -196°C to create a "regenerative reserve" of the customer's own stem cells. From these banked cells, Acorn produces personalized YOU™ secretome serums — full-spectrum preparations containing growth factors, exosomes, cytokines, and peptides — applied during clinical procedures (microneedling for skin rejuvenation; targeted delivery for hair growth support). Initial clinical data reports VEGF concentrations at 20x and EGF at 10x compared to a patient's own PRP.

The company serves three primary customer segments: aesthetic/cosmetic patients seeking skin rejuvenation, hair restoration seekers, and longevity/health-optimization enthusiasts pursuing biological insurance for future regenerative therapies. Revenue is generated through one-time collection and processing fees (~$945+tax), recurring annual or multi-year cryogenic storage fees ($190/year for individuals; multi-year prepaid packages at $1,650 for 5 years and $2,450 for 10 years), and per-treatment YOU™ secretome administration fees (~$945). Distribution operates through a hybrid model: a network of licensed provider clinics that perform collection and administer treatments, a direct e-commerce customer portal, and an Acorn Concierge clinic-matching service. Marketing leans heavily on content/earned media (Forbes, TechCrunch, Goop, Allure, Fast Company) and a referral program offering $190 account credits.

The company is in early commercial scale-up. It has raised approximately $14.3M CAD in cumulative funding (a $3.3M seed in 2019 and an $11M CAD Series A in June 2024 led by Merz Aesthetics), holds under 50 employees, operates dual Canadian and US legal entities, and is expanding into the US market with a clinical trial (NCT07227883) underway for facial skin rejuvenation. The CEO is founder Dr. Drew Taylor, and the Director of Product Development and Innovation is Amatullah Fatehi.

Acorn Biolabs firmographics

Firmographics
Name
Acorn Biolabs
Legal name
Acorn Biolabs, Inc.
Website
https://acorn.me
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Acorn Biolabs is a Toronto-based biotech (founded 2017) that non-invasively collects and cryopreserves customers' hair follicle stem cells, then produces personalized YOU™ secretome serums for skin rejuvenation and hair growth, selling direct to consumers and through a licensed provider clinic network.
Ownership category
akta.pro rank

Acorn Biolabs industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell banking
  • Regenerative medicine
  • Cryopreservation services
  • Autologous cell therapy
  • Personalized secretome treatments

Where Acorn Biolabs is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Acorn Biolabs business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Cell Banking Services: One-time collection and processing fees plus recurring annual or multi-year storage fees for cryopreservation of hair follicle stem cells. Collection appointments at partner clinics cost approximately $945+ tax, with storage plans ranging from $190/year to $1,650 for 10 years for individuals.
  2. YOU™ Secretome Products: Personalized regenerative treatments (skin and hair) derived from the patient's own banked stem cells. These are applied through licensed provider clinics during procedures like microneedling. Initial clinical data shows significantly higher growth factor concentrations (VEGF at 20x, EGF at 10x) compared to PRP.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractCollection + 5 Years Storage
One time/ perpetual licenseMulti-year contractCollection + 10 Years Storage
SubscriptionAnnualIndividual Annual Storage
SubscriptionAnnualFamily Annual Storage

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Acorn Biolabs product offering

Product offering

Core offering

Acorn Biolabs collects, processes, and cryopreserves customers' own hair follicle-derived stem cells at -196°C for lifetime storage, then uses those banked cells to manufacture personalized secretome serums applied during clinical aesthetic procedures (e.g., microneedling) for skin rejuvenation and hair growth. The offering combines an upfront cell collection service with recurring cryogenic storage and downstream personalized regenerative treatments delivered through a network of licensed provider clinics.

Product overview

Acorn Biolabs offers a personalized regenerative medicine platform centered on hair follicle-derived stem cell banking and secretome-based treatments. The core offering consists of Cell Banking (cryopreservation of the customer's own stem cells harvested from hair follicles), paired with two personalized secretome serum products: YOU™ for Skin (for facial rejuvenation via microneedling) and YOU™ for Hair (for hair growth support). The secretome products are produced by culturing and processing the customer's banked cells to generate a concentrated regenerative serum containing growth factors, exosomes, and other bioactive molecules. A Future Pipeline extends into anti-aging, joint repair, and broader regenerative medicine applications. All treatments use the customer's own (autologous) cells, eliminating immune rejection risks.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell Banking Cryopreservation service that collects and stores customers' hair follicle stem cells at -196°C for lifetime preservation, including initial collection of 50 hair follicles, laboratory processing, viability analysis, and long-term cryogenic storage for future regenerative treatments.
  • YOU™ for Skin A personalized secretome serum made from the customer's own banked stem cells, applied during microneedling procedures for facial skin rejuvenation. Contains concentrated growth factors and regenerative signals derived from the patient's hair follicle stem cells.
  • YOU™ for Hair A personalized secretome serum derived from the customer's own banked stem cells, designed to support natural, long-term hair growth at a cellular level by delivering concentrated regenerative signals to hair follicles.
  • Acorn Concierge Provider Matching Personal concierge service that matches customers with licensed clinic providers in the Acorn network based on their treatment goals and geographic location.

Quantifiable outcome

  • Growth factor concentrations in secretome show VEGF at 20x and EGF at 10x compared to patient's own PRP
  • +3 more outcomes

Companies that use Acorn Biolabs

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Acorn Biolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Acorn Biolabs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dr. Steven YoelincoreStrategic or Co-development Partner · 10 March 2026Dr. Steven Yoelin is serving as the principal investigator leading the randomized, blinded, controlled clinical trial (NCT07227883) evaluating YOU™ secretome product for facial skin rejuvenation. The trial is being conducted at a single investigational site in Newport Beach, California.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Acorn Biolabs competitors and assessment

Company assessment

Emerging players

  • ExoCoBio: ExoCoBio is a South Korea-based exosome aesthetics company producing EXOVEL and other stem cell-derived exosome skincare products used in aesthetic clinics. It competes directly with YOU™ for Skin in the same provider channel.
  • Stemson Therapeutics: Stemson is a San Diego-based regenerative medicine company developing iPSC-derived hair follicle therapies for hair loss. It addresses the same hair restoration use case as Acorn's YOU™ for Hair, but via a different (iPSC, allogeneic) technical approach.
  • Kimera Labs: Kimera Labs is a regenerative medicine company producing exosome-based products for both aesthetic and therapeutic indications, including skincare and hair restoration. It targets the same physician channel as Acorn with cell-derived regenerative products.
  • BENEV Company: BENEV is a US medical aesthetics company that pioneered exosome-based regenerative skincare (Exosome Regenerative Complex) for in-office aesthetic procedures, making it a direct competitor to Acorn's YOU™ secretome microneedling offering.

Broad incumbents

  • EmCyte Corporation: EmCyte is an established regenerative medicine device company producing PRP and concentrated bone marrow aspirate systems used in aesthetic and orthopedic procedures. It is the incumbent against which YOU™ secretome competes on growth factor concentration.

Direct peers

  • Forever Labs: Forever Labs is the most direct peer to Acorn, offering cryopreservation of young adult stem cells (from whole blood or adipose) for future regenerative use, targeting similar longevity and health-optimization consumers with a comparable subscription-based storage model.
  • Cryo-Cell International: Cryo-Cell is a publicly traded cell banking company specializing in cryopreservation of cord blood and menstrual blood-derived stem cells. It shares Acorn's core cryopreservation business model, though it focuses on different cell sources and a more traditional family/newborn banking customer base.
  • ViaCord: ViaCord (owned by Revvity/PerkinElmer) is a major cord blood and cord tissue banking service operating the same subscription-based cryopreservation business model as Acorn, although it focuses on newborn cells rather than adult hair follicle stem cells.
  • Cord Blood Registry (CBR): CBR, now part of CooperSurgical, is the largest US cord blood bank with a similar recurring-storage subscription model and direct-to-consumer acquisition approach, addressing expectant parents seeking biological insurance for their children.
  • StemCyte: StemCyte is a global cord blood and cellular therapy company operating a cryopreservation business closely comparable to Acorn's, including public cord blood banking and regenerative medicine research applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Acorn Biolabs social profiles

Digital presence

Acorn Biolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acorn Biolabs leadership team

Management profile

Number of profiles

Profiles4 records

Acorn Biolabs funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acorn Biolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acorn Biolabs

What does Acorn Biolabs do?

Acorn Biolabs collects, processes, and cryopreserves customers' own hair follicle-derived stem cells at -196°C for lifetime storage, then uses those banked cells to manufacture personalized secretome serums applied during clinical aesthetic procedures (e.g., microneedling) for skin rejuvenation and hair growth. The offering combines an upfront cell collection service with recurring cryogenic storage and downstream personalized regenerative treatments delivered through a network of licensed provider clinics.

Is Acorn Biolabs a public or private company?

Acorn Biolabs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Acorn Biolabs founded?

Acorn Biolabs was founded in 2017. It employs 11 to 50 people.

Where is Acorn Biolabs based?

Acorn Biolabs is headquartered in Toronto, Canada, in the North America region.

How does Acorn Biolabs make money?

Two revenue lines are on record. Cell Banking Services are the primary driver. The others are YOU™ Secretome Products.

Who are Acorn Biolabs's main competitors?

Emerging players on record are ExoCoBio, Stemson Therapeutics, Kimera Labs and BENEV Company. EmCyte Corporation is listed as a broad incumbent. Direct peers are Forever Labs, Cryo-Cell International, ViaCord, Cord Blood Registry (CBR) and StemCyte.

Does Acorn Biolabs have an API?

No public API is recorded for Acorn Biolabs.

What industry is Acorn Biolabs in?

Acorn Biolabs's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Fast CompanyThis company wants to use AI to reverse aging — here’s howAcorn Biolabs founder Drew Taylor discusses using AI to predict stem cell performance from a single image and build personalized treatment plans. The company aims to reverse aging through regenerative medicine, and the episode also examines societal readiness for longer life.Men's HealthStem Cell Skin Care: I Tried a Secretome Serum From My HairThe author tried Acorn Biolabs' secretome serum, a stem-cell-derived product, after microneedling. It healed faster than usual, with less irritation, but no control was used. The author notes the science is promising but lacks large-scale validation.GlossyWellness Briefing: How stem cell therapy innovator Acorn Biolabs is (legally) scaling in the US, plus newsAcorn Biolabs, a Canadian regenerative medicine company, is scaling its stem cell therapy product called "You" in the U.S. market by partnering with American doctors. The company's CEO Drew Taylor discussed the expansion strategy in an interview, positioning stem cells as a growing trend in the wellness space. The briefing also briefly notes other wellness industry news including a CVS executive departure and Merrithew's investment in gyrokinesis.Longevity.TechnologyIf you could freeze a healthier version of yourself…Acorn Biolabs preserves hair follicle stem cells from patients, creating secretome products for skin and hair restoration. The company also explores cartilage, pancreatic, and neuronal applications, aiming for future regenerative therapies. The approach targets aging prevention by storing cells before damage accumulates.EIN PresswireAcorn Biolabs Advances Autologous Regenerative Platform with Injectable Clinical Study for Facial RejuvenationAcorn Biolabs announced that the first patients have been treated in a randomized, blinded, controlled clinical trial evaluating its autologous hair-follicle secretome product (YOU™) for facial skin rejuvenation, including intra-dermal facial and cannula under-eye injections. The trial (NCT07227883) will quantitatively measure changes in skin quality including wrinkles, roughness, elasticity, pigmentation, and safety outcomes, with four patients also participating in a blinded biopsy sub-study. The study is being conducted at a single investigational site led by Dr. Steven Yoelin in Newport Beach, California, with CEO Dr. Drew Taylor describing it as a milestone toward generating high-quality clinical data in the aesthetic market.ForbesHow To Try A ‘Secretome’ Skincare Serum From Your Stem CellsAcorn Biolabs, a Toronto-based regenerative medicine company, soft-launched personalized secretome serums in November 2024, made from a patient's own banked stem cells harvested non-invasively from hair follicles and applied during microneedling procedures. The journalist became the first U.S. media member to try this personalized secretome serum during a microneedling appointment with Dr. Ben Talei in Beverly Hills, reporting positive results including improved skin texture and bounce, with initial clinical data showing significantly higher growth factor concentrations (e.g., VEGF at 20x, EGF at 10x) compared to the patient's own PRP. While the regenerative aesthetics field is gaining momentum, experts note significant cost barriers (approximately $945 USD plus annual fees under $150 USD) and ongoing questions about long-term efficacy compared to established treatments like nanofat or donor-derived alternatives.ZieringmedicalHair Transplant Treatments and Technology Advances in 2025Ziering Medical, led by Dr. Craig Ziering, has outlined its comprehensive hair restoration treatments and technologies for 2025, including stem cell banking in partnership with Acorn Biolabs, laser hair therapy using the Z CAP device, topical treatment Z-Factors, KeraLase™ procedure, and the MDEE hair transplant technique.NewBeautyUnderstanding Hyper-Personalization in BeautyThe article explores the emerging trend of hyper-personalization in the beauty industry, where technology is used to create custom-made products tailored to individual skin types and preferences. It features insights from experts at Perfect Corp., Scentronix, Acorn Biolabs, and medical professionals regarding this technological shift.Techplus MediaAcorn Biolabs Secures $11M CAD in Series A Funding to Advance Cell Preservation for Regenerative MedicineToronto-based biotech startup Acorn Biolabs has secured $11 million CAD in Series A funding led by Merz Aesthetics to advance its cell preservation services for regenerative medicine. The company plans to use the capital to expand its commercial presence and develop personalized cosmetic products derived from hair follicle cells.